Daratumumab for familial cavernous malformations
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation clinical trials.
This study tests a medication called daratumumab to see if it is safe and helps people with familial cerebral cavernous malformations (CCM). The drug is given as an infusion and may slow down or prevent new bleeding or symptoms from these brain blood vessel clusters.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need to have a condition called familial cerebral cavernous malformations (familial CCM) – that means you have more than one cavernous malformation in your brain or you have at least two family members with these malformations.
- You must have had symptoms or a history of problems like bleeding in the brain, stroke, seizures, or other neurological issues.
- Your doctor must have said surgery is not a good option for you.
- You must be willing to come to the hospital for check-ups and give written consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to best treat people with untreated cerebral cavernous malformations (a cluster of abnormal blood vessels in the brain). It compares outcomes between those who have surgery and those who are monitored with regular check-ups, and will follow participants for a long time to see how they do.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
This study follows people with a hereditary form of cavernous malformations (clusters of abnormal blood vessels in the brain). It aims to understand how the condition changes over time, without testing any new treatments.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial tests a drug called daratumumab for people with certain HIV-related blood cancers (primary effusion lymphoma, plasmablastic lymphoma) or a related condition called multicentric Castleman disease that has come back or not improved after standard treatment. The drug targets a protein on cancer cells to help the immune system attack them. It might be a new option when standard chemotherapy isn't working or isn't suitable.
Hear when a new Cavernous Malformation, Cerebral trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.